CreditRiskMonitor is a financial risk analysis and news service for credit, supply chain and financial professionals.  Our strength in coverage spans 58,000 global public companies, totaling about $70 trillion in corporate revenue.  We also offer solutions that can help ease private company financial risk assessment.  Leading corporations around the world – including more than 35% of the Fortune 1000, plus thousands more worldwide – rely on us to help them stay ahead of financial risk quickly, accurately and cost-effectively. 

A partial report preview for Laekna Inc is shown below.  Where indicated by "Yes," CreditRiskMonitor contains this information in its extensive database.  To get access to the full report and learn more about CreditRiskMonitor's robust financial risk analysis and timely news service, request a personalized demo and free trial today.

If you are already a subscriber and want to access the full report, click here.

Laekna Inc
SHANGHAI, SHA  200120  China Ticker: 21052105

Business Summary
Laekna Inc is an investment holding company mainly engaged in the discovery, development and commercialization of innovative therapies for cancer and liver disease. The Company is mainly engaged in the research and development of drug candidates for monotherapy and combination therapy, focusing on the treatment of various cancers and liver fibrosis diseases. The Company's main product pipelines include LAE002 and LAE001. The LAE002 is an adenosine triphosphate (ATP) competitive AKT inhibitor for the treatment of ovarian cancer, prostate cancer, breast cancer and PD-1/PD-L1 drug-resistant solid tumors. The LAE001 is an androgen synthesis inhibitor that simultaneously inhibits cytochrome P450 family 17 subfamily A member 1 (CYP17A1) and cytochrome P450 family 11 subfamily B member 2 (CYP11B2) for the treatment of prostate cancer. The Company mainly conducts its businesses in China, the United States, Europe and South Korea.

Scores and Ratings
FRISK®
Score
Z''
Score
PAYCE®
Score
DBT
Index
Moody's
Rating
Fitch
Rating
DBRS
Rating
YesYes-----

Financials, News and Filings
Latest
Statement
Last
Audit

News
SEC
Filings
Bankruptcy
Filings
Suit &
Judgment
Filings
Tax
Lien
Filings
12/31/202312/31/2022Yes----

Officers and Directors

Title

Name

Age
Title
Date
Start
Date
Executive Chairman of the Board, Chief Executive Officer XiangyangLu 59 5/1/2022 7/29/2016
Chief Financial Officer, Executive Director Kwok KeungChau 47 1/15/2024 1/15/2024
Senior Vice President, Executive Director LingXie 52 5/1/2022 4/1/2017
10 additional Officers and Directors records available in full report.

General Information
Number of Employees: 89 (As of 12/31/2023)
Outstanding Shares: 390,100,350 (As of 12/31/2023)
Stock Exchange: HKG


Copyright © 2024 CreditRiskMonitor.com (Ticker: CRMZ). All rights reserved.     
By using this website, you accept the Terms of Use Agreement.
Saturday, April 27, 2024